Bienaime Jean Jacques: insider trades.
Bienaime Jean Jacques reported 4 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 4 open-market purchases ($514K) and 0 sales, across 2 companies.
- Transactions
- 4
- Purchases (P)
- 4
- Sales (S)
- 0
- Companies
- 2
- Name as filed
- BIENAIME JEAN JACQUES
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Keros Therapeutics, Inc. (KROS) | Director | 2 |
| Ascendis Pharma A/S (ASND) | Director | 2 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-17 | Keros Therapeutics, Inc. | P | 1,000 | $10.27 | 19,592 | Form 4 |
| 2026-08-14 | Ascendis Pharma A/S | P | 1,100 | $245.85 | 2,000 | Form 4 |
| 2026-08-14 | Ascendis Pharma A/S | P | 900 | $246.91 | 2,900 | Form 4 |
| 2026-07-15 | Keros Therapeutics, Inc. | P | 1,000 | $10.61 | 18,592 | Form 4 |
Questions
What stock did Bienaime Jean Jacques buy or sell?
Bienaime Jean Jacques reported 4 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 4 open-market purchases ($514K) and 0 sales, across 2 companies.
Is Bienaime Jean Jacques the same person as other filers with this name?
This page covers SEC CIK 1221590 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/bienaime-jean-jacques-1221590.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.